Volume 10,Issue 7
Objective: To evaluate the efficacy and symptom scores of early diabetic nephropathy (DKD) treated with modified Shenqi Dihuang Decoction. Methods: 82 patients with early DKD who visited the hospital from February 2023 to February 2025 were randomly divided into two groups by drawing. Group A received modified Shenqi Dihuang Decoction + SGLT2 inhibitor, while Group B received SGLT2 inhibitor only. The efficacy, symptom scores, blood glucose, and renal function were compared between the two groups. Results: The efficacy of Group A was higher than that of Group B in the treatment of early DKD (P < 0.05). The DKD symptom scores of Group A were lower than those of Group B (P < 0.05). The fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG), and glycated hemoglobin (HbA1c) of Group A were better than those of Group B (P < 0.05). The serum creatinine (SCr), blood urea nitrogen (BUN), and urinary albumin excretion rate (UAER) of Group A were also better than those of Group B. Conclusion: The combination of modified Shenqi Dihuang Decoction and SGLT2 inhibitor dapagliflozin has excellent efficacy in the treatment of early DKD, which can improve renal function, reduce DKD symptoms, and stabilize blood glucose levels.